Disease-modifying antirheumatic drugs are commonly used to treat rheumatoid arthritis, but prolonged usage often results in drug related toxicity, loss of effi cacy, or both. The molecular mechanisms that might be involved in the development of resistance to such drugs, and strategies to overcome this phenomenon, are outlined.
- Joost W van der Heijden
- Ben AC Dijkmans
- Gerrit Jansen
